These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1746446)

  • 21. Coronary patency after thrombolysis.
    Van de Werf F
    Z Kardiol; 1993; 82 Suppl 2():171-4. PubMed ID: 8328197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Indirect criteria of coronary reperfusion and permeability in patients with acute myocardial infarction who have received thrombolytic therapy].
    Pereira MA; Albuquerque A; Azevedo JG; Torres S; Gomes L; Campos M; Pimenta A
    Rev Port Cardiol; 1991 Mar; 10(3):229-35. PubMed ID: 1854515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
    Berrocal DH; Cohen MG; Spinetta AD; Ben MG; Rojas Matas CA; Gabay JM; Magni JM; Nogareda G; Oberti P; Von Schulz C; Doval H; Bazzino OO; Cagide A; Oliveri R; Grinfeld LR
    Am Heart J; 2003 Dec; 146(6):E22. PubMed ID: 14661011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
    White HD
    Am J Cardiol; 1998 Oct; 82(8B):57P-62P. PubMed ID: 9809893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators.
    Karagounis L; Moreno F; Menlove RL; Ipsen S; Anderson JL
    Am J Cardiol; 1991 Oct; 68(9):848-56. PubMed ID: 1927942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Hillis WS; Hornung RS; Hogg KJ; Hockings N; Burns JM; Dunn FG
    Drugs; 1987; 33 Suppl 3():117-23. PubMed ID: 3315576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
    Lincoff AM; Topol EJ
    Circulation; 1993 Sep; 88(3):1361-74. PubMed ID: 8353902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considerations affecting selection of thrombolytic agents.
    Smitherman TC
    Mol Biol Med; 1991 Apr; 8(2):207-18. PubMed ID: 1806763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis.
    Norris RM; White HD; Cross DB; Woo KS; Elliott JM; Twigden D; Williams B; Johnson RN
    Br Heart J; 1993 Jun; 69(6):485-91. PubMed ID: 8343313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
    Weaver WD
    Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of thrombolytic therapy for acute myocardial infarction.
    Reiner JS; Wasserman AG
    Coron Artery Dis; 1994 May; 5(5):373-9. PubMed ID: 7921367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of early coronary patency on the evolution of myocardial infarction: a prospective arteriographic study.
    Timmis AD; Griffin B; Crick JC; Nelson DJ; Sowton E
    Br Heart J; 1987 Oct; 58(4):345-51. PubMed ID: 3314951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative effectiveness of intracoronary and systemic thrombolytic therapy of acute myocardial infarction].
    Khalfen ESh; Shtern SV; Shvarts IL; Bezrukova GA; Zolotarev VA; Rakovskiĭ ME
    Kardiologiia; 1989 Aug; 29(8):15-9. PubMed ID: 2685445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion.
    Wong CK; French JK; Krucoff MW; Gao W; Aylward PE; White HD
    Eur Heart J; 2002 Sep; 23(18):1449-55. PubMed ID: 12208225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Summary of U.S. clinical trials program for evaluation of anistreplase.
    Anderson JL
    Clin Cardiol; 1990 Mar; Suppl 5():V33-8; discussion V67-72. PubMed ID: 2182239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolytic therapy of acute myocardial infarction.
    de Bono DP
    Baillieres Clin Haematol; 1995 Jun; 8(2):403-12. PubMed ID: 7549070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombotic and thrombolytic therapies for acute myocardial infarction.
    Godfried SL; Gaziano JM; Hennekens CH
    J Cardiovasc Risk; 1996 Oct; 3(5):453-7. PubMed ID: 9048261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.